Shunichiro Miki

Dr. Shunichiro Miki

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in Science
Verified
Journal Article
Closed access
KKKsenia Krupina
Ksenia Krupina
AGAlexander Goginashvili
Alexander Goginashvili
MBMichael W. Baughn
Michael W. Baughn
SMStephen Moore
Stephen Moore
CSChristopher D. Steele
Christopher D. Steele
DCDon W. Cleveland
Don W. Cleveland
Genome instability, including chromothripsis, is a hallmark of cancer. Cancer cells frequently contain micronuclei—small, nucleus-like structures formed by chromosome missegregation—that are susceptible to rupture, exposing chromatin to cytoplasmic nucleases. Through an unbiased, imaging-based small interfering RNA screen that targeted all 204 known and putative human nucleases, we identified a previously uncharacterized cytoplasmic endonuclease, NEDD4-binding protein 2 (N4BP2), that enters ruptured micronuclei and initiates DNA damage, leading to chromosome fragmentation. N4BP2 promoted genome rearrangements (including chromothripsis), formation of extrachromosomal DNA (ecDNA) in drug-induced gene amplification, tumorigenesis, and tumor cell proliferation in an induced model of human high-grade glioma. Analysis of more than 10,000 human cancer genomes revealed elevated N4BP2 expression to be predictive of chromothripsis and copy number amplifications, including ecDNA.


12 June 2025 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
KAKazuki Akutagawa
Kazuki Akutagawa
SMShunichiro Miki
Shunichiro Miki
EYErika Yamada
Erika Yamada
NSNoriaki Sakamoto
Noriaki Sakamoto
TMTSUBASA MIYAZAKI
TSUBASA MIYAZAKI
EIEiichi Ishikawa
Eiichi Ishikawa
Background: Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, characterized by high invasiveness and a poor prognosis, with limited treatment options. Our previous study on fractionated radiotherapy, temozolomide, and an autologous formalin-fixed tumor vaccine (AFTV) for newly diagnosed grade 4 astrocytic tumors demonstrated that complete tumor resection and p53 negativity on immunohistochemistry were associated with favorable outcomes. PIK3R2, a key component of the PI3K–Akt signaling pathway, may modulate the host immune response to tumor antigens and influence the efficacy of immunotherapy. In this study, we further investigated whether PIK3R2, a candidate gene identified through gene panel sequencing as potentially associated with prognosis following AFTV treatment, influences patient outcomes after AFTV therapy. Methods: We analyzed 58 patients with newly diagnosed IDH wildtype GBM or IDH mutant grade 4 astrocytoma (Astro). Among them, 29 received standard treatment combined with AFTV (AFTV group), while 29 underwent standard treatment alone (control group). Immunostaining for PIK3R2 and p53 was performed, and patient characteristics, including age, sex, Karnofsky Performance Status at the time of surgery, and overall survival (OS), were evaluated. PIK3R2 expression levels were classified using a 34% cutoff value. Results: In the AFTV group, survival analysis based on PIK3R2 status (positive/negative) revealed an increased survival in the PIK3R2-negative group when comparing AFTV and control groups (p = 0.075 in GBM/Astro cases and p = 0.030 in GBM cases). When stratifying patients into four subgroups based on p53 and PIK3R2 status (p53-negative/PIK3R2-negative, p53-positive/PIK3R2-positive, p53-negative/PIK3R2-positive, and p53-positive/PIK3R2-negative), a significant improvement in OS was observed in the p53-negative/PIK3R2-negative group both in GBM/Astro cases and GBM cases. PD-1 demonstrated the strongest correlation with PIK3R2 in the regression analysis. Conclusion: Negative immunostaining for PIK3R2 as well as negative p53 revealed an increased survival in patients receiving AFTV therapy for GBM. In patients receiving AFTV, these immunostaining results may serve as a predictor of treatment efficacy and overall survival.

2 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TITakumi Inaba
Takumi Inaba
NSNarushi Sugii
Narushi Sugii
HKHidehiro Kohzuki
Hidehiro Kohzuki
SMShunichiro Miki
Shunichiro Miki
TTTAKAO TSURUBUCHI
TAKAO TSURUBUCHI
EIEiichi Ishikawa
Eiichi Ishikawa
Background/Objective: Intraoperative local photodynamic therapy (PDT) using talaporfin sodium (TS) and photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) are valuable adjuncts in the treatment of malignant brain tumors. Although their concomitant use was previously contraindicated due to photosensitivity concerns, a 2022 regulatory revision permitted their combined application. Transient postoperative hyperintensity on diffusion-weighted imaging (DWI) at the irradiation site serves as a biomarker for PDT effects, but the radiological and clinical impact of combining 5-ALA and TS remains unclarified. To compare and evaluate postoperative DWI findings and clinical outcomes in patients undergoing TS-PDT with or without concomitant 5-ALA-guided PDD. Methods: This retrospective study analyzed 34 patients with recurrent primary malignant brain tumors who underwent TS-PDT between January 2019 and November 2025. Patients were divided into a TS alone group (n = 19) and a TS + 5-ALA group (n = 15). Postoperative DWI hyperintensity thickness and minimum apparent diffusion coefficient (ADC) values at the laser irradiation site were measured. Adverse events including photosensitivity were also compared. Results: No significant differences were observed between the TS alone and TS + 5-ALA groups in DWI hyperintensity thickness (3.71 mm vs. 3.90 mm; p = 0.703 or median ADC values (601.0 × 10−6 mm2/s vs. 527.0 × 10−6 mm2/s; p = 0.205). Furthermore, there were no significant differences in the incidence of photosensitivity and liver enzyme elevation. Conclusions: Concomitant use of 5-ALA-PDD and TS-PDT can be used without worsening DWI findings at the PD laser irradiation site.

28 September 2026 in Neuro-Oncology
Verified
Journal Article
Open access
DKDaisuke Kawauchi
Daisuke Kawauchi
YMYohei Miyake
Yohei Miyake
BTBrett Taylor
Brett Taylor
JBJoseph Bendik
Joseph Bendik
SMShunichiro Miki
Shunichiro Miki
FFFrank Furnari
Frank Furnari
Background: Mutations in the telomerase reverse transcriptase (TERT) promoter region (TPM), particularly C228T and C250T, are common in IDH-wildtype glioblastoma (GBM). The single nucleotide polymorphism (SNP) rs2853669, also located in the TERT promoter, may influence telomerase activity, though its clinical relevance in GBM remains unclear. This study examined the allelic configuration between rs2853669 and TPM to elucidate their combined effects on TERT expression and clinical outcome. Methods: Seventy-six TPM-positive GBM tumors from Japanese patients were analyzed by nested PCR, and patients were classified by rs2853669 genotype (T/T, T/C, C/C). In the T/C subgroup, the allelic configuration between the SNP and TPM was determined as cis (same allele) or trans (different alleles). Clinical data, TERT expression, and prognosis were compared among groups. Results: Among 76 patients, 37 (48.7%) had T/T, 30 (39.5%) had T/C, and 9 (11.8%) had C/C genotypes. The rs2853669 C allele frequency was higher in GBM than in the general Japanese population (31.6% vs 24.5%, P = .047). Among T/C cases, 53.3% showed a cis configuration. Patients carrying the SNP and TPM on the same allele (C/C and T/C cis) had shorter overall survival than those carrying them on different alleles (T/T or T/C trans; 19 vs 25 months, P = .048), and TERT expression was also lower in this group (P = .038). Conclusion: The rs2853669 C allele may increase GBM susceptibility and, when in cis with TPM, is associated with reduced TERT expression and poorer prognosis, underscoring its biological and clinical significance in TPM-mutant GBM.